Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
For example, semaglutide 2.4mg (Wegovy) has demonstrated approximately 15% weight loss in clinical trials for obesity, while liraglutide 3mg (Saxenda) typically achieves 5-10% weight loss
Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) Once-Weekly Semaglutide for Weight Management: A Clinical Review
Side-by-side comparison Factor Receptor targets Semaglutide GLP-1 only Tirzepatide GLP-1 + GIP Retatrutide GLP-1 + GIP + glucagon Liraglutide GLP-1 only Factor Half-life Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Liraglutide ~13 hours Factor Dosing frequency Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Liraglutide Once daily Factor Max studied dose Semaglutide 2.4 mg/week (SubQ)
A systematic review and meta-analysis published in PMC found that cagrilintide actually had the lowest odds ratio for nausea, vomiting, and diarrhea compared to other incretin-based therapies
It is good for both weight management and health as a whole
